BCG-Unresponsive NMIBC Treatment Strategies with Expert Urologists

Alhamdulillah!🎉 I am very happy to share that my first Review article has been published. Our review article, "Therapeutic Strategies for Downregulating Isocitrate Dehydrogenase in the Treatment of Glioblastoma Multiforme," focuses on new therapeutic approaches for treating glioblastoma, including CRISPR gene editing, nanomedicine, lipid nanoparticles, and targeted therapies. This is an important milestone in my academic journey and brings me one step closer to my goal of contributing to neuro-oncology and brain cancer research. I am thankful to my supervisor, Dr Fawad ur Rehman, Dr Rida-e-Maria Qazi, Asif Shah, and all other group members for their support and guidance throughout this journey. https://lnkd.in/d7YhEUxv #AKU #Neuro-oncology #Publication

Since 2022, I have been part of a team funded by Cancer Grand Challenges focused on understanding the causes of and finding new treatments for #cachexia, the unintended and usually extreme weight loss that often occurs in advanced #cancer. The team found somewhat counterintuitively that a high fat diet can worsen symptoms of cachexia in mouse models carrying a mutation often found in #lungcancer. Learn more below. Eileen White Tobias Janowitz Marcus Goncalves #TeamCANCAN

Researchers have uncovered a previously unrecognized pathway linking lung tumor genetics, diet, and the nervous system that drives cancer-associated cachexia, according to a new Science study in mice. The findings suggest that this newly identified tumor-to-nerve signaling pathway could present a potential therapeutic target for the condition. 📄: https://scim.ag/4oYIU5T #SciencePerspective: https://scim.ag/4oYIUmp

New highlights from the Regenerative Medicine journal are here 📖 Commissioning Editor Jasmine Hagan breaks down her standout articles from our sister journal: 🔬 Next-gen scaffold design for tendon tissue engineering 🧬 The evolving promise of stem cell gene therapy for metabolic diseases 🩺 What drives patient trust in stem cell treatments and why it matters Read the full highlights and explore the research >>> https://hubs.ly/Q04nVjwq0

Prof. Annalisa Ruggeri is a true advocate for cord blood transplantation, with long-standing dedication to research and education in this field. 👇 Three core points: 1. Cord blood transplantation remains irreplaceable Unmatched low GVHD and quality-of-life advantages for children and patients with inherited disorders. 2. Best option for MRD-positive high-risk leukemia HLA loss-driven relapse is extremely rare, offering unique long-term disease control. 3. Ideal platform for cell and gene therapy Cord blood-derived NK/CAR cell therapy is already in clinical trials, and regenerative medicine is exploring tissue repair applications. #hematology #oncology #OncoFrontier

📃 READ DESCRIBTION BELOW A schematic representation of the in vivo mouse models currently available for cancer research. Carcinogen-induced mouse models are induced to develop certain types of cancer by exposing them to certain environmental risk factors (carcinogenic chemicals, radiation, etc.). Syngeneic mouse models are immunocompetent animals that bear tumors of mouse origin. CDX models are immunodeficient mouse models, and tumors are implanted to assess drug function on a tumor. GEMM models are mouse strains that have been manipulated genetically either by the overexpression of an oncogene or by the loss of a tumor suppressor gene function. PDX models are immunocompromised animals implanted with tumors of human origin. Humanized PDX models can represent the human immune system to a certain extent along with tumors of human origin to study tumor–immune system interactions Yu JZ, Kiss Z, Ma W, Liang R, Li T. Preclinical Models for Functional Precision Lung Cancer Research. Cancers (Basel). 2024 Dec 25;17(1):22. doi: 10.3390/cancers17010022. PMID: 39796653; PMCID: PMC11718887. #Gesundheit #Bildung #Fuehrung #Coaching #Mindset #Motivation #Gehirn #Neuroscience #Psychologie #Persoenlichkeitsentwicklung #Kindheit #KeyNoteSpeaker #Humangenetik #Biochemie #Neuroleadership #Ernaehrung #Transformation #Stress #Demografie #Gender #Age #interkulturelleKompetenz #Epigenetik #Veraenderung #EmotionaleIntelligenz #Change #Gesellschaft #Organisationsentwicklung #Philosophie #Beratung # Quantum

Safusidenib Delivers Long-Term Benefit in Grade 2 IDH1-Mutant Glioma Long-term follow-up continues to reinforce the potential of safusidenib for patients with IDH1-mutant grade 2 glioma. Updated Phase 2 results demonstrated a confirmed objective response rate (ORR) of 52%, with 79% of patients remaining progression-free at 36 months after nearly 40 months of median follow-up. The durable efficacy, coupled with a favorable safety profile, supports the ongoing global Phase 3 trial evaluating safusidenib in patients with newly diagnosed grade 2 IDH1-mutant glioma, bringing the therapy one step closer to potential regulatory submission. #NovationBio #Safusidenib #IDH1 #IDH1Mutant #Glioma #Grade2Glioma #BrainTumor #NeuroOncology #Oncology #Phase2 #Phase3 #ClinicalTrials #PrecisionMedicine #DrugDevelopment #Biotechnology https://lnkd.in/deDH5ynJ Image Credit: Magnific

A fluorescence image is captivating, but Cryo-Fluorescence Tomography (CFT) produces far more than a captivating image. By pairing fluorescent signal with true anatomical structure across the whole specimen, CFT gives researchers a volumetric understanding of biodistribution, disease progression, or protein expression. See what that looks like in our gallery of CFT images from oncology, neuroscience, gene & cell therapy, and drug delivery studies: 🔗 https://bit.ly/4borlq2 If you're curious how this could apply to your own research, hop on a quick call with our team. In just a few minutes, we can walk you through example images and the quantitative insights behind them. Schedule here: https://bit.ly/4wmYOsX #PreclinicalImaging #Biodistribution #CryoFluorescenceTomography #GeneTherapy #Oncology #fluorescencefriday

I’m honored to share that our review article has been published in Bone Marrow Transplantation (BMT), a Nature Portfolio journal and one of the leading international journals in hematopoietic stem cell transplantation. Our review provides a comprehensive overview of nonmyeloablative (NMA) and reduced-intensity conditioning (RIC) strategies for allogeneic hematopoietic stem cell transplantation in sickle cell disease, examining the evolving evidence on engraftment, graft-versus-host disease, survival outcomes, quality of life, and the expanding role of haploidentical transplantation. It also discusses remaining challenges, including optimization of donor chimerism, minimizing long-term toxicities, and the future integration of transplantation with emerging gene therapies. I am especially grateful to Dr. Ghada ElGohary for her exceptional mentorship, insightful guidance, and unwavering support throughout this project. Her expertise, dedication to scientific excellence, and encouragement made this work possible and have been invaluable to my development as a researcher. Read the full article here: https://lnkd.in/eUEmYb_U #NaturePortfolio #BoneMarrowTransplantation #Hematology #StemCellTransplantation #SickleCellDisease #MedicalResearch #AcademicMedicine #ResearchPublication

Pleased to invite you all to a very interesting read! Our latest work published in Brain Journal, in collaboration with the amazing Davila-Velderrain lab, reveals a disrupted WWOX-MYC axis underlying aberrant cellular differentiation and maturation trajectories in WOREE and SCAR12 patient-derived neural organoids. More on this here: https://lnkd.in/esG8-gE4. This study underscores both the non-cell- and cell-autonomous roles of WWOX in the brain and builds on years of foundational work in the lab that was pivotal in bringing WWOX neuronal gene therapy to life. Very heartfelt thanks to my true mentor, Rami Aqeilan, for his vision and unwavering support, the patients, my co-first authors, our collaborators in the Stern lab and everyone involved in this study.